AUTHORS
Jonathan R Day, PharmD, MD, Melissa Larson, MS2, Laura Magnano, MD, PhD3, Eric Mou, MD4, Urshila Durani, MD, MPH5, Mazie Tsang, MD, MAS, MS6, Umar Farooq, MD7, Arushi Khurana, MBBS8, Patrizia Mondello, MD, PhD9, Jose C Villasboas, MD10, Gita Thanarajasingam, MD11, Ivana Micallef, MD12, Carrie Thompson, MD13, Sergei Syrbu, MD14, Andrew L. Feldman, MD15, Jonathan W. Friedberg, MD16, Philippe Armand, MD17, Stephen Maxted Ansell, MD, PhD18, Thomas Witzig, MD19, Thomas M. Habermann, MD20, James R. Cerhan, MD, PhD21, Brian K Link, MD22, Yucai Wang, MD, PhD23, Matthew E. Maurer, ScD24
AFFILIATIONS
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 University of Iowa, Iowa City, Iowa, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Phoenix, Arizona, United States
7 University of Iowa, Iowa City, Iowa, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 Mayo Clinic, Rochester, Minnesota, United States
10 Mayo Clinic, Rochester, Minnesota, United States
11 Mayo Clinic, Rochester, Minnesota, United States
12 Mayo Clinic, Rochester, Minnesota, United States
13 Mayo Clinic, Rochester, Minnesota, United States
14 University of Iowa, Iowa City, Iowa, United States
15 Mayo Clinic, Rochester, Minnesota, United States
16 University of Rochester, Rochester, New York, United States
17 Mayo Clinic, Rochester, Minnesota, United States
18 Mayo Clinic, Rochester, Minnesota, United States
19 Mayo Clinic, Rochester, Minnesota, United States
20 Mayo Clinic, Rochester, Minnesota, United States
21 Mayo Clinic, Rochester, Minnesota, United States
22 University of Iowa, Iowa City, Iowa, United States
23 Mayo Clinic, Rochester, Minnesota, United States
24 Mayo Clinic, Rochester, Minnesota, United States
ABSTRACT
Introduction: Follicular lymphoma (FL) has traditionally been considered incurable, yet emerging data increasingly challenge this notion. Data from SWOG S0016 suggest that up to 40% of patients treated with immunochemotherapy (IC) may be cured. Long-term follow-up of patients with FL enrolled in the Molecular Epidemiology Resource (MER) has also shown a decrease in the rate of progressions and retreatments in the 2nd decade from diagnosis. In order to better understand the curability of of FL,we compared the incidence of late lymphoma events in FL to those from subtypes traditionally considered curable: diffuse large B-cell lymphoma (DLBCL) and classical Hodgkin lymphoma (cHL).
Methods: Patients with grade 1-3A FL, DLBCL, and cHL diagnosed between 2002-2015 and enrolled in the MER were included if they received frontline immunochemotherapy treatment for FL (R-CHOP, R-CVP, & BR) or anthracycline-based curative intent therapy for DLBCL or cHL. Based on S0016 and prior MER analysis, a landmark time of 10 years from diagnosis was selected for patients with FL. For patients with DLBCL and cHL, a 5-year landmark from diagnosis was selected, as patients achieving event free survival (EFS) at this time point are conventionally considered to be cured. Analysis was restricted to patients who were event free at these landmarks from start of 1L therapy. Mutually exclusive first events post-landmark were classified as lymphoma events (including progression, initiation of 2nd-line treatment, or transformation for patients with FL, as non-death events (NDE) and lymphoma death (LD)), non-lymphoma death, or death from unknown cause. Cumulative incidences were estimated in a competing-risks framework, with first lymphoma event, or other death were treated as competing events. Cause of death was analyzed separately and included deaths after a prior NDE.
Results: Median follow-up from diagnosis in the MER cohort was 15 years (IQR 12-18 years). 189/452 patients with FL treated with IC achieved the 10-year EFS landmark; 771/1328 patients with DLBCL and 337/503 patients with cHL achieved the 5-year EFS landmark. Patients with FL who achieved the landmark had a median age of 68 years (IQR 60-76) at landmark. Among evaluable patients, there were 27% with high risk FLIPI and 17% with high risk FLIPI24 at diagnosis. 1L FL regimens included R-CHOP (44%), R-CVP (25%), and BR (28%) and other (3%), with 36% receiving maintenance rituximab. Patients with DLBCL had a median age of 68 years (IQR 58-76) at landmark, and 22% had high-intermediate IPI (3) and 12% high IPI (4-5) at diagnosis. 1L regimens included R-CHOP or like therapy (88%), R-EPOCH or like (6%), and other intensive regimens. Patients with cHL who achieved landmark had a median age of 43 years (IQR 32-55) at landmark and a median IPS of 1 (IQR 1-2) at diagnosis. 1L treatment of cHL included ABVD or AVD (96%), Stanford V (2%), and others (2%).
After the landmark the cumulative incidences of late lymphoma-related events were 3.3% (2.7% NDE; 0.6% LD) at 5 years and 6.4% (5.8 NDE, 0.6%LD) at 10 years for FL . No transformations were observed as late lymphoma events after the landmark. The corresponding cumulative incidences were 4.9% (3.4% NDE, 1.5% LD) at 5 years and 10.5% (6.2% NDE; 4.3% LD) at 10 years for DLBCL and 1.0% (0.6% NDE, 0.4 %LD) at 5 years and 3.1% (2.2% NDE; 0.9% LD) at 10 years for cHL.
Separate cause of death analysis in patients who achieved the landmark showed that risk of lymphoma-related death was low across the lymphoma subtypes. after the landmark, the incidence of LD was 0.6% (95% CI 0.1-4.5%) at 5 and 10 years for FL, 2.5% (1.6-4%) at 5 years and 6.6% (4.9-8.9%) at 10 years for DLBCL, and 0.6% (0.2-2.6%) at 5 years and 1.2% (0.4-4%) at 10 years for cHL.
Conclusions: Among patients with FL treated with 1L IC, who remained event free 10 years, subsequent lymphoma related events were uncommon. The rate of late events in FL is similar to those of DLBCL and cHL after 5 years, a milestone where the concept of cure is commonly accepted for those subtypes. These data further support the concept of curability for FL.
DISCLOSURES
Jonathan R Day, PharmD, MD: No relevant conflicts of interest to declare.